Development of an HPLC method for monitoring of Photofrin II therapy

Michael Vogeser, Moshe Schaffer, Emil Egeler, Ute Spöhrer

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer. After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II. The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting. The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity-representing the main side effect of Photofrin II-with the perspective of individualized light protection regimens after Photofrin II administration.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalClinical Biochemistry
Issue number1
StatePublished - 1 Jan 2005
Externally publishedYes


  • HPLC
  • Photodynamic therapy
  • Photofrin II
  • Phototoxicity
  • Porphyrins
  • Radiodynamic therapy

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Development of an HPLC method for monitoring of Photofrin II therapy'. Together they form a unique fingerprint.

Cite this